Stockscreener 앱 받기
0.6943
0.86%
0.0059
시장 영업 전:
.67
-0.0243
-3.50%
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Income Statement - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.695|Chg%:+0.006 - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.690|Chg%:+0.002 - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.688|Chg%:-0.041 - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.650|Chg%:-0.038 - TradingKey
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR - TradingView
Jasper Therapeutics Market Sentiment - Benzinga España
Jasper Therapeutics Inc. (JSPR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement - Bitget
Form 4 Jasper Therapeutics Inc For: 22 July By Investing.com - Investing.com Canada
Jasper Therapeutics (JSPR) COO buys non-voting convertible preferred shares - Stock Titan
Jasper Therapeutics (JSPR) EVP outlines option and preferred stakes after Kira deal - Stock Titan
Jasper Therapeutics (JSPR) COO discloses merger-converted option stakes - Stock Titan
Form 4 Jasper Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
Jasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement - Bitget
Jasper Therapeutics (JSPR) director buys preferred stock, granted stock options - Stock Titan
Jasper Therapeutics (JSPR) director details common and preferred stake - Stock Titan
Jasper closes Kira deal, extends cash runway - MSN
Jasper Therapeutics (JSPR) holders outline 3,349,547-share stake after Kira deal - Stock Titan
Jasper Therapeutics stock trades sideways as cash position and clinical pipeline shape outlook - Ad-hoc-news.de
Jasper Therapeutics Completes Kira Acquisition and PIPE Financing - The Globe and Mail
Jasper Closes Kira Deal, Extends Cash Runway - Benzinga
Jasper gets a lifeline in merger with immune drugmaker Kira - BioPharma Dive
Jasper completes Kira merger, lines up $132 million financing - The Pharma Letter
Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026 - marketscreener.com
Patrick Crutcher appointed to Jasper Therapeutics board; Matthew Ros named COO - TradingView
Jasper Therapeutics (NASDAQ: JSPR) buys Kira, adds $132M PIPE cash - Stock Titan
Jasper Therapeutics acquires Kira, extends cash runway - TipRanks
Jasper Therapeutics acquires Kira Pharmaceuticals for $132m - Investing.com UK
Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy - Bitget
$Jasper Therapeutics (JSPR.US)$ - Moomoo
Jasper Therapeutics acquires Kira Pharmaceuticals for $132m By Investing.com - Investing.com Nigeria
Jasper Therapeutics: Jeet Mahal to Be Pres and CEO of Combined Co - Moomoo
Jasper Therapeutics Merges With Kira Pharmaceuticals - Moomoo
Jasper Therapeutics merges with Kira Pharmaceuticals, raising $132M to advance immunology drug pipeline. - Pluang
Jasper Therapeutics: Combined Co Will Focus on Advancing Consolidated Pipeline of Potential Best-In-Class Innovative Therapies for Immunologically-Driven Disorders >JSPR - Moomoo
Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028 - TradingView
Jasper Therapeutics (NASDAQ: JSPR) closes Kira merger and $132M preferred financing - Stock Titan
Press Release: Jasper Therapeutics Announces Merger With Kira Pharmaceuticals - Moomoo
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals in all-stock deal - Bitget
Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):